e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Tyra Biosciences, Inc. - Common Stock (NQ:TYRA)

26.22 -0.47 (-1.76%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tyra Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗

May 17, 2026

Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗

March 20, 2026

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

Via The Motley Fool

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗

March 19, 2026

Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.

Via The Motley Fool

Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗

March 19, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.

Via The Motley Fool

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Via The Motley Fool

Topics Regulatory Compliance

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

February 23, 2026

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally ↗

December 23, 2025

Focused on precision oncology and rare genetic diseases, this biotech reported a significant insider sale amid strong one-year stock gains.

Via The Motley Fool

Topics Regulatory Compliance

Tyra Biosciences Narrows Loss in Q2 ↗

August 14, 2025

Via The Motley Fool

Which stocks are moving before the opening bell on Tuesday? ↗

April 22, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 22, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 22, 2025

Via Benzinga

Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗

April 22, 2025

Via Benzinga

Why WaFd Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗

April 14, 2025

Via Benzinga

Why Penguin Solutions Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

April 03, 2025

Via Benzinga

Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 17, 2025

Via Benzinga

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗

March 17, 2025

Via Benzinga

Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

January 02, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 29, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 25, 2024

Via Benzinga

Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? ↗

October 25, 2024

Tyra Biosciences shares TYRA-300 Phase 1/2 data in metastatic urothelial cancer with 100% disease control at ≥90 mg doses and favorable safety.

Via Benzinga

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug ↗

October 18, 2024

Tyra Biosciences receives an upgrade from BofA, raising the price target to $31. The upgrade follows promising preclinical data for TYRA-300 and increased sales projections for metastatic urothelial...

Via Benzinga

This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

October 18, 2024

Via Benzinga

TYRA Investors Have Opportunity to Join Tyra Biosciences, Inc. Securities Fraud Investigation with the Schall Law Firm

August 20, 2024

From The Schall Law Firm

Via Business Wire

TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q2 2024 ↗

August 07, 2024

TYRA stock results show that Tyra Biosciences beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday ↗

July 12, 2024

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy